Literature DB >> 2523548

Effect of paroxetine on the electrocardiogram.

J G Edwards1, A Goldie, S Papayanni-Papasthatis.   

Abstract

The electrocardiographic effects of paroxetine have been studied. High speed electrocardiograms were recorded on 20 patients with major depression before and after 4 weeks' treatment with either paroxetine or placebo. No patient had a history or clinical evidence of cardiovascular disease. The ECG measurements were made blind to patient, treatment and treatment interval. No significant changes in heart rate, PR, and QTc intervals or in T-wave height were found after treatment with active drug or placebo but there was a small increase from 81 to 85 ms in the QRS width in the paroxetine group which was significantly different from the small decrease that occurred in the placebo group. No significant changes in blood pressure were noted. The findings show that paroxetine has no clinically relevant cardiac effects when given in therapeutic doses to relatively young healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523548     DOI: 10.1007/bf00443420

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  14 in total

1.  Potent and long-lasting potentiation of two 5-hydroxytryptophan- induced effects in mice by three selective 5-ht uptake inhibitors.

Authors:  J B Lassen
Journal:  Eur J Pharmacol       Date:  1978-02-01       Impact factor: 4.432

2.  Determination of paroxetine in human plasma, using high-performance liquid chromatography with fluorescence detection.

Authors:  M A Brett; H D Dierdorf; B D Zussman; P E Coates
Journal:  J Chromatogr       Date:  1987-08-07

3.  Electrophysiologic precursors of ventricular tachyarrhythmias.

Authors:  J Han; B G Goel
Journal:  Arch Intern Med       Date:  1972-05

4.  Central and peripheral 5-HT uptake in rats treated chronically with femoxetine, paroxetine, and chlorimipramine.

Authors:  J B Lassen; J Lund; I Søndergaard
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

5.  Comparative effects of fluoxetine and amitriptyline on cardiac function.

Authors:  J W Upward; J G Edwards; A Goldie; D G Waller
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

6.  The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations.

Authors:  E G Giardina; J T Bigger; A H Glassman; J M Perel; S J Kantor
Journal:  Circulation       Date:  1979-11       Impact factor: 29.690

7.  Electrocardiogram changes and plasma desipramine levels during treatment of depression.

Authors:  R C Veith; R O Friedel; V Bloom; R Bielski
Journal:  Clin Pharmacol Ther       Date:  1980-06       Impact factor: 6.875

8.  Influence of the new 5-HT-uptake inhibitor paroxetine on hypermotility in rats produced by p-chloroamphetamine (PCA) and 4,alpha-dimethyl-7-tyramine (H 77/77).

Authors:  J B Lassen
Journal:  Psychopharmacology (Berl)       Date:  1978-04-28       Impact factor: 4.530

9.  Placebo-controlled trial of mianserin and maprotiline in primary depressive illness: a preliminary report.

Authors:  J G Edwards; A Goldie
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

10.  An early clinical phase II evaluation of paroxetine, a new potent and selective 5HT-uptake inhibitor in patients with depressive illness.

Authors:  C Børup; B Meidahl; I M Petersen; A Vangtorp; P le Fèvre Honoré
Journal:  Pharmacopsychiatria       Date:  1982-11
View more
  11 in total

1.  Selective serotonin reuptake inhibitors.

Authors:  J G Edwards
Journal:  BMJ       Date:  1992-06-27

2.  Cardiovascular effects of paroxetine.

Authors:  H Kuhs; G A Rudolf
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Systematic review and guide to selection of selective serotonin reuptake inhibitors.

Authors:  J G Edwards; I Anderson
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

4.  Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia.

Authors:  Charles E Leonard; Warren B Bilker; Craig Newcomb; Stephen E Kimmel; Sean Hennessy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-07-28       Impact factor: 2.890

Review 5.  Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  K L Dechant; S P Clissold
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 6.  Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.

Authors:  S M Holliday; G L Plosker
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 7.  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Authors:  Peter M Haddad; Ian M Anderson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Authors:  R H Foster; K L Goa
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

Review 9.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

10.  Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study.

Authors:  Elena Qirjazi; Eric McArthur; Danielle M Nash; Stephanie N Dixon; Matthew A Weir; Akshya Vasudev; Racquel Jandoc; Lorne J Gula; Matthew J Oliver; Ron Wald; Amit X Garg
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.